X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11255) 11255
Newsletter (175) 175
Magazine Article (28) 28
Book Chapter (20) 20
Dissertation (19) 19
Publication (8) 8
Book Review (5) 5
Transcript (5) 5
Conference Proceeding (4) 4
Newspaper Article (4) 4
Web Resource (4) 4
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7318) 7318
clarithromycin (6772) 6772
male (4124) 4124
female (3989) 3989
clarithromycin - therapeutic use (2992) 2992
anti-bacterial agents - therapeutic use (2968) 2968
helicobacter pylori (2894) 2894
middle aged (2831) 2831
adult (2826) 2826
helicobacter infections - drug therapy (2718) 2718
pharmacology & pharmacy (2412) 2412
drug therapy, combination (2155) 2155
microbiology (2074) 2074
infection (2034) 2034
aged (2005) 2005
anti-bacterial agents - pharmacology (1843) 1843
gastroenterology & hepatology (1793) 1793
helicobacter pylori - drug effects (1720) 1720
clarithromycin - pharmacology (1701) 1701
treatment outcome (1658) 1658
clarithromycin - administration & dosage (1600) 1600
microbial sensitivity tests (1411) 1411
anti-bacterial agents - administration & dosage (1391) 1391
amoxicillin (1383) 1383
infectious diseases (1369) 1369
antibiotics (1257) 1257
eradication (1197) 1197
azithromycin (1142) 1142
metronidazole (1130) 1130
amoxicillin - therapeutic use (1111) 1111
adolescent (1025) 1025
helicobacter infections - microbiology (1009) 1009
animals (993) 993
erythromycin (980) 980
therapy (943) 943
resistance (861) 861
triple therapy (796) 796
anti-bacterial agents - adverse effects (789) 789
infections (779) 779
omeprazole (775) 775
anti-ulcer agents - therapeutic use (762) 762
helicobacter pylori - isolation & purification (761) 761
amoxicillin - administration & dosage (751) 751
clarithromycin - adverse effects (749) 749
drug resistance, bacterial (746) 746
omeprazole - therapeutic use (742) 742
medicine, general & internal (706) 706
child (701) 701
prospective studies (690) 690
macrolides (675) 675
efficacy (663) 663
aged, 80 and over (642) 642
health aspects (621) 621
drug administration schedule (611) 611
antibiotic-resistance (601) 601
prevalence (599) 599
lansoprazole (592) 592
management (573) 573
levofloxacin (568) 568
metronidazole - therapeutic use (554) 554
children (528) 528
immunology (523) 523
susceptibility (522) 522
omeprazole - administration & dosage (519) 519
research (519) 519
helicobacter infections (513) 513
drug therapy (505) 505
pharmacokinetics (493) 493
proton pump inhibitors (492) 492
helicobacter pylori - genetics (491) 491
time factors (483) 483
disease (481) 481
clarithromycin resistance (477) 477
care and treatment (473) 473
bacterial infections and mycoses (467) 467
2-pyridinylmethylsulfinylbenzimidazoles (464) 464
analysis (464) 464
child, preschool (460) 460
mice (460) 460
drug resistance, microbial (456) 456
anti-ulcer agents - administration & dosage (455) 455
helicobacter infections - diagnosis (451) 451
drug interactions (450) 450
drug resistance (440) 440
omeprazole - analogs & derivatives (440) 440
young adult (439) 439
helicobacter infections - complications (435) 435
in-vitro (419) 419
erythromycin - pharmacology (416) 416
antimicrobial resistance (414) 414
biopsy (407) 407
diagnosis (392) 392
mycobacterium infections, nontuberculous - drug therapy (392) 392
retrospective studies (390) 390
risk factors (390) 390
double-blind method (386) 386
metronidazole - administration & dosage (378) 378
follow-up studies (369) 369
drug resistance in microorganisms (367) 367
respiratory system (359) 359
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10370) 10370
Japanese (542) 542
Spanish (254) 254
French (205) 205
German (155) 155
Chinese (86) 86
Russian (74) 74
Korean (64) 64
Polish (34) 34
Italian (30) 30
Turkish (26) 26
Portuguese (25) 25
Hungarian (17) 17
Dutch (16) 16
Czech (13) 13
Danish (5) 5
Swedish (5) 5
Ukrainian (4) 4
Hebrew (3) 3
Norwegian (2) 2
Romanian (2) 2
Slovenian (2) 2
Bulgarian (1) 1
Persian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2016, Volume 151, Issue 1, pp. 51 - 69.e14
Background & Aims Helicobacter pylori infection is increasingly difficult to treat. The purpose of these consensus statements is to provide a review of the... 
Gastroenterology and Hepatology | Resistance | Rifabutin | Levofloxacin | Clarithromycin | Helicobacter pylori | Proton Pump Inhibitor | Amoxicillin | Bismuth | Metronidazole | Eradication | Tetracycline | CONTAINING QUADRUPLE THERAPY | CONTAINING TRIPLE-THERAPY | CONCOMITANT THERAPY | ANTIBIOTIC-RESISTANCE | SEQUENTIAL THERAPY | RANDOMIZED CONTROLLED-TRIAL | CLINICAL-PRACTICE GUIDELINES | STANDARD TRIPLE | LEVOFLOXACIN-CONTAINING TRIPLE | GASTROENTEROLOGY & HEPATOLOGY | Bismuth - standards | Bismuth - administration & dosage | Drug Administration Schedule | Humans | Metronidazole - administration & dosage | Clarithromycin - standards | Proton Pump Inhibitors - standards | Amoxicillin - standards | Anti-Infective Agents - standards | Metronidazole - standards | Canada | Anti-Infective Agents - administration & dosage | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Levofloxacin - standards | Clarithromycin - administration & dosage | Adult | Amoxicillin - administration & dosage | Tetracycline - standards | Tetracycline - administration & dosage | Drug Therapy, Combination - standards | Levofloxacin - administration & dosage | Care and treatment | Continuing medical education | Surgical clinics | Children's hospitals | Helicobacter infections | Adults | Epidemiology | Antiulcer drugs
Journal Article
Gut, ISSN 0017-5749, 11/2010, Volume 59, Issue 11, pp. 1465 - 1470
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2010, Volume 8, Issue 1, pp. 36 - 41.e1
Journal Article
Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
Gastroenterology, ISSN 0016-5085, 2007, Volume 132, Issue 7, pp. 2313 - 2319
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 3/2012, Volume 47, Issue 3, pp. 276 - 283
In recent years in Japan, the rate of clarithromycin (CAM) resistance in Helicobacter pylori has risen to around 30%, and the eradication rate with triple... 
Eradication of Helicobacter pylori | Large-scale observational study | Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Oncology | Internal Medicine | Rabeprazole | Surgical Oncology | Triple therapy | Clarithromycin resistance | Eradication of Helicobacter pylori - Clarithromycin resistance | LANSOPRAZOLE | MANAGEMENT | DUODENAL-ULCER | OMEPRAZOLE | SMOKING | DOSE CLARITHROMYCIN | PROTON PUMP INHIBITOR | DOUBLE-BLIND | RESISTANCE | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Multivariate Analysis | Prospective Studies | Humans | Middle Aged | Drug Resistance, Bacterial | Helicobacter pylori - drug effects | Male | Dose-Response Relationship, Drug | Young Adult | Anti-Bacterial Agents - therapeutic use | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Anti-Ulcer Agents - therapeutic use | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Clarithromycin - adverse effects | Japan | Anti-Ulcer Agents - adverse effects | Clarithromycin - therapeutic use | Anti-Ulcer Agents - administration & dosage | Adolescent | Amoxicillin - therapeutic use | Sex Factors | Amoxicillin - adverse effects | Aged | Helicobacter pylori - isolation & purification | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Anti-Bacterial Agents - administration & dosage | Helicobacter Infections - microbiology | Allergy | Endoscopic surgery | Medical colleges | Clarithromycin | Diarrhea | Antibacterial agents | Patient compliance | Allergic reaction | Antiulcer drugs | Helicobacter pylori | Analysis | Gastrointestinal diseases | Amoxicillin | Penicillin | Proton pump inhibitors | Respiratory tract diseases | Endoscopy | Universities and colleges | Drugs | Protons | Hypersensitivity | Ulcers | Sex | Multivariate analysis
Journal Article
Blood, ISSN 0006-4971, 2008, Volume 111, Issue 3, pp. 1101 - 1109
Journal Article
Journal of gastroenterology and hepatology, ISSN 0815-9319, 2012, Volume 27, Issue 5, pp. 888 - 892
Background and Aim:  Helicobacter pylori eradication clearly decreases peptic ulcer recurrence rates. H. pylori eradication is achieved in 70–90% of cases, but... 
Helicobacter pylori | clarithromycin‐resistant strain | Helicobacter pylori eradication therapy | Lactobacillus gasseri | probiotics | Probiotics | Helicobacterpylori eradication therapy | Helicobacterpylori | Clarithromycin-resistant strain | Helicobacter pylori eradication therapy | MULTICENTER | LARGE-SCALE | CLARITHROMYCIN-RESISTANT | INTERLEUKIN-8 | SUPPLEMENTATION | clarithromycin-resistant strain | Helicobacter pylori | DOUBLE-BLIND | TRIPLE THERAPY | BIFIDOBACTERIUM-CONTAINING YOGURT | INFECTION | GNOTOBIOTIC MURINE MODEL | GASTROENTEROLOGY & HEPATOLOGY | Helicobacter pylori - immunology | Anti-Ulcer Agents - therapeutic use | Humans | Middle Aged | Breath Tests | Helicobacter pylori - genetics | Drug Resistance, Bacterial | Male | Clarithromycin - therapeutic use | Combined Modality Therapy | Yogurt | Rabeprazole | Antibiosis | Helicobacter Infections - therapy | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use | Amoxicillin - therapeutic use | Intention to Treat Analysis | Female | Lactobacillus | Clarithromycin | rRNA | rRNA 23S | Clinical trials | BID protein | Infection | Polymerase chain reaction | Urea | Motivation | peptic ulcers | Amoxicillin | Feces | Mutation | DNA sequencing | Clinical Trials and Therapeutics
Journal Article
Journal Article
British journal of clinical pharmacology, ISSN 0306-5251, 2013, Volume 76, Issue 3, pp. 455 - 466
Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
P‐glycoprotein | rivaroxaban | drug interactions | cytochrome P450 | healthy subjects | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism
Journal Article